Ohta K, Kawachi E, Inoue N, Fukasawa H, Hashimoto Y, Itai A, Kagechika H
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan.
Chem Pharm Bull (Tokyo). 2000 Oct;48(10):1504-13. doi: 10.1248/cpb.48.1504.
Several pyridine- and pyrimidine-carboxylic acids were synthesized as ligand candidates for retinoid nuclear receptors, retinoic acid receptors (RARs) and retinoic X receptors (RXRs). Although the pyridine derivatives, 6-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]pyri dine-3-carboxylic acid (2b) and 6-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]py ridine-3-carboxylic acid (5b) are more potent than the corresponding benzoic acid-type retinoids, Am80 (2a) and Am580 (5a), the replacement of the benzene ring of Am580 (5a), Am555 (6a), or Am55 (7a) with a pyrimidine ring caused loss of the retinoidal activity both in HL-60 cell differentiation assay and in RAR transactivation assay using COS-1 cells. On the other hand, pyrimidine analogs (PA series, 10 and 11) of potent RXR agonists (retinoid synergists) with a diphenylamine skeleton (DA series, 8 and 9) exhibited potent retinoid synergistic activity in HL-60 cell differentiation assay and activated RXRs. Among the synthesized compounds, 2-[N-n-propyl-N-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)a mino]pyrimidine-5-carboxylic acid (PA013, 10e) is most active retinoid synergist in HL-60 assay.
合成了几种吡啶和嘧啶羧酸作为类视黄醇核受体、维甲酸受体(RARs)和维甲酸X受体(RXRs)的配体候选物。尽管吡啶衍生物6-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]吡啶-3-羧酸(2b)和6-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)羧酰胺基]吡啶-3-羧酸(5b)比相应的苯甲酸型类视黄醇Am80(2a)和Am580(5a)更有效,但用嘧啶环取代Am580(5a)、Am555(6a)或Am55(7a)的苯环在HL-60细胞分化试验和使用COS-1细胞的RAR反式激活试验中均导致类视黄醇活性丧失。另一方面,具有二苯胺骨架(DA系列,8和9)的强效RXR激动剂(类视黄醇增效剂)的嘧啶类似物(PA系列,10和11)在HL-60细胞分化试验中表现出强效的类视黄醇增效活性并激活了RXRs。在合成的化合物中,2-[N-正丙基-N-(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基]嘧啶-5-羧酸(PA013,10e)是HL-60试验中活性最强的类视黄醇增效剂。